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Abstract Serum amyloid A protein (SAA) is a human plasma
protein that has been recognized as potential biomarker of mul-
tiple ailments including myocardial infarction, in£ammatory dis-
ease and amyloiosis. Presented here is the application of a novel
immunoassay technique, termed mass spectrometric immunoas-
say for the detection and identi¢cation of SAA present in human
plasma. Results demonstrate the ability to readily detect known
SAA isotypes, and to identify novel truncated forms of SAA, in
the plasma of healthy individuals and those su¡ering from acute
and chronic in£ammation. The approach represents a rapid and
sensitive means for the routine structural characterization of
known SAA isotypes and the discovery of associated post-trans-
lational modi¢cations.
& 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Serum amyloid A (SAA) is an acute phase protein that has
in recent years become recognized as a potential biomarker of
various ailments. SAA describes a complex family of four
genes found in many species including humans [1]. Three of
these genes are commonly expressed in humans (SAA1, SAA2
and SAA4), producing proteins that act as apolipoproteins by
chaperoning in the transport of high-density lipoprotein par-
ticles [2]. During ‘acute phase response’ ^ the body’s reaction
to the immediate onset of in£ammatory stimulus with the
purpose of counteracting the challenges of tissue injury, in-
fection and trauma [3,4] ^ SAA1 and SAA2 levels in plasma
have been shown to increase as much as 1000-fold from basal
concentration of V1^5 mg/l [5]. Accordingly, SAA1 and
SAA2 (collectively referred to as SAA or A-SAA [6]) have
been recognized as particularly useful biomarkers in the as-
sessment of cardiac arrest or other in£ammatory ailments
[5,7]. Moreover, SAA has long been associated with amyloid
plaque formation, which has been connected with numerous
dysfunctions including Alzheimer’s disease and multiple scle-
rosis [8^10]. These plaques are the result of an accumulation
of truncated insoluble amyloid ¢brils, composed of the last
50^75 N-terminal amino acids of the parent SAA protein. The
appearance of these amyloid ¢brils is believed to be caused by
a naturally occurring catabolic process of SAA by a number
of cell-associated and serum proteases [11^14]. Because of this
catabolic process, it is currently believed that chronic in£am-
matory conditions (e.g. rheumatoid arthritis) and recurrent
acute phase episodes (e.g. tuberculosis) lead to more pro-
nounced levels of truncated SAA and increased amyloid
plaque formation [15,16].
Typically, conventional immunoassay approaches, and im-
muno-staining techniques, are used in the quanti¢cation of
plasma levels and in identifying amyloid plaques in tissues,
respectively [6,7]. Regarding the quanti¢cation of SAA, im-
munoassays are commercially available that are able to deter-
mine a composite SAA level in plasma (i.e. all isotypes of
SAA), however, they are unable to readily discriminate be-
tween speci¢c isotypes or variants of SAA [6]. Because SAA
is a polymorphic protein, with SAA1 and SAA2 having three
(K, L, Q) and two allelic variants (K, L), respectively [17], this
inability poses a potential problem in the study of SAA in
that the expression of some allelic forms has been found to be
race dependent [18]. This problem is compounded even fur-
ther when the possibility of producing multiple, post-transla-
tional variants of each gene product is considered.
Modern mass spectrometry (MS) techniques are able to
assist in the characterization of SAA by readily discriminating
between variant forms of the protein through direct measure-
ment of molecular mass. Indeed, Ducret et al., have used a
method consisting of a 2D-gel electrophoresis preparation fol-
lowed by liquid chromatography/electrospray ionization MS
in the characterization of SAA from the sera of an aggres-
sively in£amed individual [19]. This work successfully demon-
strated the value of using a MS-based proteomics approach in
characterizing multiple known isotypes of SAA, and more
importantly, in the identi¢cation of as-yet undiscovered iso-
types of the protein that would have otherwise been di⁄cult
to detect and characterize using immunoassay approaches.
However, although the proteomics approach used by Ducret
et al. is well suited for the general analysis of large numbers of
proteins in plasma, it can be improved upon in the speci¢c by
targeting only SAA from plasma, thereby eliminating the two
orthogonal separation techniques (2DGE and LC) needed for
preparation prior to MS. Presented here is the development of
a mass spectrometric immunoassay (MSIA) in which isotypes/
variants of SAA are selectively retrieved from human plasma
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(using pan antibodies toward all forms of SAA immobilized
onto the stationary phase of an a⁄nity pipette) and analyzed
using matrix-assisted laser desorption/ionization time-of-£ight
mass spectrometry (MALDI-TOF MS). Results are given il-
lustrating the ability to use this MSIA approach to simulta-
neously detect and di¡erentiate between SAA1K and SAA2K,
to identify as-yet unknown variants of the proteins, and to
screen for di¡erence is SAA composition between individuals.
2. Materials and methods
2.1. Study subjects
Blood samples collected from six individuals of Caucasian origin,
four males (ages ranging from 26 to 49), and two females (ages 32 and
48). The male subjects were healthy individuals, but both females were
su¡ering from in£ammation at the time samples were collected. Hu-
man blood was obtained from subjects recruited within Intrinsic Bio-
probes, Inc. (IBI), following a procedure approved by the IBI’s In-
stitutional Review Board, and after each subject had signed an
Informed Consent form.
2.2. Sample preparation
Whole blood samples (100 Wl) were acquired under sterile condi-
tions through a lancet-punctured ¢nger using two non-heparinized
(50 Wl volume) microcolumns (Drummond Scienti¢c Co., Broomall,
PA, USA). Each whole blood sample was immediately combined with
200 Wl HEPES bu¡ered saline (10 mM HEPES, 150 mM NaCl, pH
7.4 (HBS)) containing 0.1% Tween-20 and 2 Wl of a protease inhibitor
cocktail set II (Calbiochem, San Diego, CA, USA) and centrifuged for
2 min (at 7000 rpm/2500Ug) to pellet red blood cells. The supernatant
(diluted plasma, 250 Wl) was decanted from each sample and trans-
ferred to a column in a 96-well titer plate for immediate analysis.
2.3. Analysis
The plasma samples were interrogated in parallel via MSIA, a hy-
brid proteomics approach that combines a⁄nity capture with MAL-
DI-TOF MS detection [20^23]. MSIA utilizes a⁄nity pipettor tips,
which can be applied to detect low-level proteins directly from crude
biological £uid by concentrating and purifying the target protein via a
repetitive pipetting action of the sample through the a⁄nity tip fol-
lowed by a stringent rinse protocol.
The plasma/HBS samples were addressed in parallel using an eight-
barreled pipette equipped with six a⁄nity pipette tips derivatized with
monoclonal antibodies speci¢c towards the acute phase response
forms of SAA (IBI). Sample incubation consisted of 50 cycles (aspi-
ration and dispensing) of 150 Wl of the sample through each MSIA-
tip. After incubation, tips were thoroughly rinsed using HBS
(10 cycles, 150 Wl), doubly distilled water (¢ve cycles, 150 Wl), 20%
acetoniltrile/1 M ammonium acetate (10 cycles, 150 Wl) and ¢nally
with doubly distilled water (15 cycles, 150 Wl). Retained proteins
were eluted by drawing 4 Wl of MALDI matrix solution (saturated
aqueous solution of sinapic acid, in 33% (v/v) acetonitrile, 0.4% (v/v)
tri£uoroacetic acid) into each tip and depositing the eluates directly
onto a 96-well formatted hydrophobic/hydrophilic contrasting MAL-
DI-TOF target [22]. Samples were allowed to air dry prior to insertion
of the MALDI target into the mass spectrometer. The total time
required for preparation of the six samples was approximately 10 min.
3. Results
Fig. 1 shows a comparison of the direct MALDI-TOF MS
analysis of human plasma and an anti-SAA MSIA analysis
taken of the same plasma. Using MSIA, SAA was selectively
extracted/concentrated from the plasma for subsequent direct
analysis using MALDI-TOF MS. The application of anti-
SAA MSIA to samples taken from six individuals resulted
in the detection of several SAA protein isoforms and variants.
Shown in Fig. 2A are the results of the anti-SAA MSIA
analyses of the samples from the four males participating in
the study. The mass spectra are dominated by the presence of
intact SAA1K (MW=11 682.7) and a naturally occurring
Fig. 1. A: MALDI-TOF MS of diluted human plasma. Only high-level proteins (i.e. albumin, Apo-C-I, etc.) are observed. B: Anti-SAA MSIA
spectrum from human plasma.
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Fig. 2. A: Results of the anti-SAA analyses of the four male study participants. Intact as well as N-terminal and C-terminal truncated versions
of SAA1K (MW=11 682.7) and SAA2K (MW=11 628.7) isotypes are present. SAA1L* (MW=11682.7) instead of SAA1L is also believed to
be present due to an absence of signal at 11 740.7 Da. B: Results of the anti-SAA MSIA analyses of the samples from in£amed individuals.
Multiple truncated peaks are still present, but are limited to the ¢rst and second N-terminal residues.
Table 1
Comparison of observed SAA species
SAA1Ka SAA1K* SAA1K* SAA1K* SAA1K* SAA1K* SAA2K SAA2K SAA2K SAA1K SAA2K
AA1-104b AA2-104 AA3-104 AA2-103 AA2-102 AA4-101 AA1-104 AA2-104 AA3-104 AA1-99; 6-104 AA2-101
11 682c 11 526 11 441 11 363 11 235 10 871 11 628 11 472 11 385 11 052; 11 058 11 052
11 682 11 525 11 441 11 368 11 237 10 875 11 053
11 680 11 523 11 438 11 626 11 469 11 383 11 048
11 685 11 529 11 441 11 052
11 684 11 529 11 443 11 054
11 683 11 526 11 441 11 631 11 472 11 386
11 683 11 527 11 442 11 629 11 473
aSAA1K is indistinguishable in molecular weight from SAA1L*(1-104).
bAmino acid residues of observed SAA form.
cTheoretical molecular weight of observed SAA form.
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post-translational modi¢cation in which the N-terminal Arg
has been cleaved (SAA1K (R-; N-terminal) ; MW=11 526.5).
The ratios of these two dominant peaks vary from sample to
sample, while several other cleavages and isoforms of SAA are
also detected in varying ratios in each of the other MS traces.
These protein isoforms include SAA1K (RS-; N-terminal
(MW=11 439.6)), SAA1K (R-; N-terminal and -Y; C-termi-
nal (MW=11 363.6)), SAA1K (R-; N-terminal and -KY;
C-terminal (MW=11 235.6)), SAA1K (RSF-; N-terminal
and -EKY; C-terminal (MW=10 872.6)), SAA2K (MW=
11 628.7), SAA2K (R-; N-terminal (MW=11 472.6), SAA2K
(RS-; N-terminal (MW=11 385.6) and SAA2K (R-; N-termi-
nal and -EKY; C-terminal (MW=11 052.6)).
The results of the anti-SAA MSIA interrogation of sample
from two females su¡ering from in£ammation are shown in
Fig. 2B. Subject 5 was 48-h post-surgery at the time of sample
collection while Subject 6 su¡ers from in£ammation in the
form of highly aggressive chronic rheumatoid arthritis. Qual-
itatively, these results are very similar to those from the four
male samples, but lacked the extended N-terminal or any C-
terminal truncations previously seen. Both traces contained
varying amounts of the intact SAA1K and SAA2K, along
with multiple truncations of each. These truncations included
the SAA1K (R-; N-terminal ; MW=11 526.5), SAA1K (RS-;
N-terminal (MW=11 439.6)), SAA2K (R-; N-terminal (MW=
11 472.6)) and SAA2K (RS-; N-terminal (MW=11 385.6)).
The qualitative results of all six analyses are summarized in
Table 1.
4. Discussion
SAA is a polymorphic protein having several di¡erent pos-
sible alleles for each isotype, with the expression ratio of these
allelic forms being race dependent. For instance, SAA1K is
80^90% dominant with SAA1Q being rarely seen in cauca-
sians, while SAA1K, L and Q are roughly evenly dispersed in
Japanese populations [18]. The spectra resulting from all of
the anti-SAA MSIA were dominated by the SAA1K pheno-
type with no detectable signal from the SAA1Q allelic form,
which is consistent with the subjects participating in this study
all being of Caucasian ancestry. With regard to the presence
of SAA1L, controversy still remains as to what is the correct
primary sequence. The accepted literature amino acid se-
quence of SAA1L has an Asp residue at position 72
(MW=11 740.7), but a con£icting sequence has been reported
by Betts et al., in which a Gly is at position 72 (SAA1L*), thus
changing the molecular mass to 11 682.7 Da [24] (the same
molecular mass as SAA1K). The lack of ion signal at
MW=11 740.7 Da in any analysis strongly suggest that the
sequence for SAA1L may be that of the con£icting sequence,
SAA1L*. Given the lack of observable signal for SAA1L, and
the fact that SAA1L* and SAA1K are of the same molecular
mass (and share sequence homology at both termini), both of
the latter species could contribute to the composite pro¢les in
exactly the same manner and are thus labeled in Fig. 2A,B as
both SAA1K and SAA1L*.
From the results of the anti-SAA MSIA analyses, we were
able to detect multiple truncations of the SAA protein in each
individual. The catabolism of SAA via cell-associated and
serum proteases have long been known [13]. As demonstrated,
anti-SAA MSIA is readily able to detect these truncated prod-
ucts in a manner entailing only a few experimental steps and
that is relatively easy to perform. To the best of our knowl-
edge, SAA1K, L* (RS-; N-terminal), SAA1K, L* (R-; N-ter-
minal and -Y; C-terminal), SAA1K, L* (R-; N-terminal and
-KY; C-terminal), SAA1K, L* (RSF-; N-terminal and -EKY;
C-terminal), SAA2K (RS-; N-terminal) and SAA2K (R-;
N-terminal and -EKY; C-terminal) detected in these analyses
have not been previously reported. Regarding the individuals
su¡ering from in£ammation, the results indicate less observ-
able truncation than in the non-in£amed individuals, which is
most easily explained by an increase in the expression of the
intact protein. However, the SAA pro¢le from the individual
su¡ering from acute in£ammation (subject 5) di¡ers from that
observed from the individual su¡ering from chronic in£am-
mation (subject 6) in the relative amount of SAA1K, L* and
SAA1K, L* (R-; N-terminal). This phenomenon was origi-
nally observed by Raynes et al., from which it was determined
that SAA without a N-terminal Arg reaches a maximum 24 h
later than the full sequence isoforms [25]. Di¡erences are also
observed in the truncated patterns of the non-in£amed indi-
viduals, most prominently in pro¢le obtained from individual
1, whom although not in any state of aggressive in£ammation
exhibited extensive breakdown products (relative to the other
individuals). Taken collectively, these results suggest that
breakdown pathways leading to the truncated products may
be in£uenced by individual phenotype as well as state of in-
£ammation.
5. Conclusion
In summary, anti-SAA MSIA analysis was used to identify
multiple forms of SAA present in the plasma of individuals.
These di¡erent forms included the known SAA1K, SAA1L
and SAA2K isotypes along with various N- and C-terminal
truncations of each, most of which have not been reported
previously. The results obtained in this small preliminary
study illustrate the need for a more concerted investigation,
involving time-course studies of large numbers of individuals
in order to monitor the progression and the formation of the
truncated forms of SAA under in£ammatory and non-in£am-
matory conditions and to decipher individual phenotypic con-
tributions. Such studies may assist in the further understand-
ing of the role of SAA with regard to in£ammatory response
and the problems associated with amyloidosis.
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